Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms

被引:83
作者
Desai, Divyakant [1 ]
Wang, Jennifer [1 ]
Wen, Hong [2 ]
Li, Xuhong [3 ]
Timmins, Peter [4 ]
机构
[1] Bristol Myers Squibb Co, Drug Prod Sci & Technol, New Brunswick, NJ 08903 USA
[2] Pentian Pharmaceut Co, Shanghai, Peoples R China
[3] US FDA, CDER, Silver Spring, MD USA
[4] Bristol Myers Squibb Co, Drug Prod Sci & Technol, Moreton, Merseyside, England
关键词
Fixed dose combination; FDC; formulations; an active coating; HME; bi-layer tablet; SUSTAINED-RELEASE; BILAYER TABLET; MATRIX TABLET; DRUG-RELEASE; IN-VITRO; DELIVERY; PELLETS; SPHERONIZATION; HYDROCHLORIDE; OPTIMIZATION;
D O I
10.3109/10837450.2012.660699
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Fixed dose combination (FDC) products are common in the treatment of hypertension, diabetes, human immunodeficiency virus, and tuberculosis. They make it possible to combine two or more drug molecules with different modes of pharmacological actions in a single dosing unit and optimize the treatment. From a patient perspective, they offer convenience, reduced dosing unit burden, and cost savings. From a clinical perspective, aging population in developed countries will need multiple medications to treat age related diseases and co-morbidities. FDC products simplify dosing regimen and enhance patient compliance. As outlined in the article, the number of FDC products has grown over the years and the trend is likely to continue. This review article gives an overview to pharmaceutical scientists about recent trends in the formulation development of the FDC products and provides decision trees to select most optimum formulation development strategy. While some formulation technologies such as multi-layer tablets, multiparticulate systems, active film coating, and hot-melt granulation are discussed in more detail, a few specialized technologies are also introduced briefly to the readers.
引用
收藏
页码:1265 / 1276
页数:12
相关论文
共 66 条
[1]   A flexible technology for modified-release drugs: Multiple-unit pellet system (MUPS) [J].
Abdul, Shajahan ;
Chandewar, Anil V. ;
Jaiswal, Sunil B. .
JOURNAL OF CONTROLLED RELEASE, 2010, 147 (01) :2-16
[2]   Mechanical Property Characterization of Bilayered Tablets using Nondestructive Air-Coupled Acoustics [J].
Akseli, Ilgaz ;
Dey, Dipankar ;
Cetinkaya, Cetin .
AAPS PHARMSCITECH, 2010, 11 (01) :90-102
[3]   Interfacial elastic relaxation during the ejection of bi-layered tablets [J].
Anuar, M. S. ;
Briscoe, B. J. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 387 (1-2) :42-47
[4]   Fixed-dose single tablet antidiabetic combinations [J].
Bailey, C. J. ;
Day, C. .
DIABETES OBESITY & METABOLISM, 2009, 11 (06) :527-533
[5]   Role of surface free energy and spreading coefficient in the formulation of active agent-layered pellets [J].
Baki, Gabriella ;
Bajdik, Janos ;
Djuric, Dejan ;
Knop, Klaus ;
Kleinebudde, Peter ;
Pintye-Hodi, Klara .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2010, 74 (02) :324-331
[6]  
Benkerrour L, 2004, US patent, Patent No. [No. US2004/0115265, 20040115265, US2004/0115265]
[7]  
Bova J, 2009, Patent No. [WO/1999/006046, 1999006046]
[8]  
CARSTENS.JT, 1970, J PHARM SCI, V59, P553
[9]  
Charlton ST, 2010, J PHARM PHARMACOL, V62, P1397
[10]  
Chen W, 2008, J PHARM INNOV, V3, P1872